CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of breast cancer.
  
  LEARNING OBJECTIVES

  • Appreciate the incidence and pathological and molecular characteristics of HER2-low and HER2-ultralow breast cancer, and understand the implications of diagnosis of these phenotypes for routine disease management.
  • Assess the biological rationale for the use of HER2-directed therapy for patients with HER2-low and HER2-ultralow breast cancer, and determine its current clinical utility in this disease subset.
  • Appraise available clinical research establishing the safety and efficacy of HER2-directed antibody-drug conjugate (ADC) therapy for patients with hormone receptor (HR)-positive and HR-negative, HER2-low metastatic breast cancer, and optimally incorporate this strategy into treatment algorithms.
  • Recognize Phase III efficacy results establishing the benefit of HER2-directed ADC therapy for patients with HR-positive, HER2-ultralow metastatic breast cancer, and consider the potential role of this novel approach.
  • Understand the spectrum, frequency and severity of treatment-emergent adverse events associated with HER2-directed ADCs, and develop strategies to monitor for, prevent and manage these complications.
  • Recall the design of ongoing clinical trials evaluating novel strategies for HER2-low and HER2-ultralow breast cancer, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 2.25 (audio) and 1.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a short post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set , complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/SABCS2024/HER2LowBC/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/SABCS2024/HER2LowBC/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/SABCS2024/HER2LowBC/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/SABCS2024/HER2LowBC.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Aditya Bardia, MD, MPH
  Professor of Medicine
  Geffen School of Medicine at UCLA
  Director, Breast Oncology Program
  Assistant Chief (Translational Research)
  Division of Medical Oncology
  Director of Translational Research Integration
  UCLA Health Jonsson Comprehensive Cancer Center
  Los Angeles, California
  
  Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Merck, Novartis, Pfizer Inc, Sanofi.
  
  Professor Giuseppe Curigliano, MD, PhD
  Clinical Director
  Division of Early Drug Development for Innovative Therapy
  Co-Chair, Cancer Experimental Therapeutics Program
  Department of Oncology and Hemato-Oncology
  University of Milano
  European Institute of Oncology
  Milano, Italy
  
  Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Lilly, Menarini Group, Merck, Novartis, Seagen Inc; Contracted Research: Merck; Data and Safety Monitoring Board/Committee: Roche Laboratories Inc; Scientific Board: Ellipses Pharma; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Merck, Novartis, Pfizer Inc.
  
  Hope S Rugo, MD
  Professor of Medicine
  Winterhof Family Professor of Breast Cancer
  Director, Breast Oncology and Clinical Trials Education
  Medical Director, Cancer Infusion Services
  University of California, San Francisco
  Helen Diller Family Comprehensive Cancer Center
  San Francisco, California
  
  Consulting Agreements: Chugai Pharmaceutical Co Ltd, Napo Pharmaceuticals Inc, Puma Biotechnology Inc, Sanofi, Viatris; Contracted Research: Ambrx, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Gilead Sciences Inc, Greenwich LifeSciences Inc, Lilly, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Stemline Therapeutics Inc.
  
  Antonio C Wolff, MD, FACP, FASCO
  Professor of Oncology
  Johns Hopkins University
  Baltimore, Maryland
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.
  
  Release date: December 2024
  Expiration date: December 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.